veski innovation fellow
Professor Colby Zaph was awarded a 3-year veski innovation fellowship in July 2015.
Research project: Biological Methylation: a new frontier in the regulation of immunity and inflammation
Mucosal tissues such as the intestine and lung form a physical barrier between the body and the outside world. Cells must differentiate between what’s good for the body, including innocuous food antigens and symbiotic bacteria, and what’s bad, including viruses, parasites and infectious bacteria. A breakdown in this ability to differentiate between good and bad often leads to chronic inflammatory diseases including asthma, inflammatory bowel diseases, food allergies and cancer.
Chronic inflammatory diseases afflict millions of people and current treatments are less than ideal. With very few Victorian researchers are focused on mucosal immunology, Professor Zaph will provide Victoria with a unique and cutting-edge approach in this important area.
The pharmaceutical market for the treatment of inflammatory diseases and immune deficiency is worth an estimated $70 billion per year. None of the drugs in the pipeline provide a first line treatment for inflammatory diseases. Colby will continue to forge strong collaborations with key industry partners with the aim of developing new drugs.
The Zaph laboratory in the Department of Biochemistry and Molecular Biology at Monash University is focused on defining the cellular and molecular mechanisms that control immunity and inflammation at these mucosal sites. This understanding represents a potential target for identifying novel therapeutics for the treatment of these diseases. Colby and his team are focusing on both immune cells (T cells) as well as non-immune cells (epithelial cells) that respond to the inflammatory signals. They are defining the role of a class of enzymes that modify proteins to change their function by a process called methylation.
The results from his experiments will begin to identify candidate compounds to translate for use into human subjects. As these inhibitors are developed in partnership with industrial partners, there are immediate opportunities for translational studies in a wide variety of inflammatory disease settings.